We are live on ! Find out more
BNTX icon

BioNTech

116.76 USD
+3.94
3.49%
At close Updated Aug 25, 11:35 AM EDT
1 day
3.49%
5 days
6.84%
1 month
28.18%
3 months
26.57%
6 months
6.3%
Year to date
20.76%
1 year
11.13%
5 years
-68.95%
10 years
719.94%
 

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Employees: 7,807

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 36%
Neutral 44%
Negative 20%
Positive
24/7 Wall Street
4 hours ago
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Negative
24/7 Wall Street
1 day ago
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of the most explosive runs in biotech this year.
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
Positive
24/7 Wall Street
4 days ago
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday.
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
Neutral
24/7 Wall Street
5 days ago
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday's historic 177% rally.
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Neutral
GlobeNewsWire
5 days ago
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer (“WCLC”) in Seoul, Republic of Korea, from September 12-15, 2026.
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
Positive
Benzinga
5 days ago
Why Is BioNTech Stock Surging on Wednesday?
BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to Merck & Co Inc. (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) topline data from individualized cancer therapy for advanced skin cancer.
Why Is BioNTech Stock Surging on Wednesday?
Neutral
The Motley Fool
12 days ago
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.
BioNTech has officially named its next CEO. The transition appears carefully planned, not reactive.
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.
Neutral
Seeking Alpha
20 days ago
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
21 days ago
BioNTech Q2 Earnings Call Highlights
BioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt out of a shingles vaccine development program.
BioNTech Q2 Earnings Call Highlights
Negative
Barrons
21 days ago
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Price charts implemented using Lightweight Charts™